Logo image of MRTX

MIRATI THERAPEUTICS INC (MRTX) Stock Fundamental Analysis

NASDAQ:MRTX - Nasdaq - US60468T1051 - Common Stock - Currency: USD

58.7  -0.1 (-0.17%)

After market: 58.99 +0.29 (+0.49%)

Fundamental Rating

4

Overall MRTX gets a fundamental rating of 4 out of 10. We evaluated MRTX against 572 industry peers in the Biotechnology industry. While MRTX has a great health rating, there are worries on its profitability. MRTX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRTX had negative earnings in the past year.
MRTX had a negative operating cash flow in the past year.
MRTX had negative earnings in each of the past 5 years.
In the past 5 years MRTX always reported negative operating cash flow.
MRTX Yearly Net Income VS EBIT VS OCF VS FCFMRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -200M -400M -600M

1.2 Ratios

MRTX has a worse Return On Assets (-64.25%) than 64.25% of its industry peers.
MRTX has a Return On Equity of -76.69%. This is comparable to the rest of the industry: MRTX outperforms 50.25% of its industry peers.
Industry RankSector Rank
ROA -64.25%
ROE -76.69%
ROIC N/A
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRTX Yearly ROA, ROE, ROICMRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

The Gross Margin of MRTX (88.50%) is better than 90.56% of its industry peers.
MRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRTX Yearly Profit, Operating, Gross MarginsMRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

MRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRTX has been increased compared to 1 year ago.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRTX Yearly Shares OutstandingMRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
MRTX Yearly Total Debt VS Total AssetsMRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 8.55 indicates that MRTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.55, MRTX belongs to the top of the industry, outperforming 83.64% of the companies in the same industry.
MRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.55
ROIC/WACCN/A
WACC10.5%
MRTX Yearly LT Debt VS Equity VS FCFMRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M -500M 1B

2.3 Liquidity

MRTX has a Current Ratio of 7.54. This indicates that MRTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.54, MRTX is doing good in the industry, outperforming 67.79% of the companies in the same industry.
A Quick Ratio of 7.39 indicates that MRTX has no problem at all paying its short term obligations.
MRTX's Quick ratio of 7.39 is fine compared to the rest of the industry. MRTX outperforms 67.28% of its industry peers.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.39
MRTX Yearly Current Assets VS Current LiabilitesMRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.74% over the past year.
MRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 223.64%.
MRTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.01% yearly.
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%

3.2 Future

The Earnings Per Share is expected to grow by 12.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 126.18% on average over the next years. This is a very strong growth
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRTX Yearly Revenue VS EstimatesMRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
MRTX Yearly EPS VS EstimatesMRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRTX Price Earnings VS Forward Price EarningsMRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRTX Per share dataMRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as MRTX's earnings are expected to grow with 12.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y12.15%

More info and screens

0

5. Dividend

5.1 Amount

MRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRATI THERAPEUTICS INC

NASDAQ:MRTX (1/22/2024, 8:00:02 PM)

After market: 58.99 +0.29 (+0.49%)

58.7

-0.1 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2023-11-06/bmo
Earnings (Next)02-26 2024-02-26/amc
Inst Owners4.62%
Inst Owner Change0%
Ins Owners10.58%
Ins Owner Change0%
Market Cap4.12B
Analysts69.09
Price Target62.42 (6.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.01%
Min EPS beat(2)6.02%
Max EPS beat(2)14.01%
EPS beat(4)4
Avg EPS beat(4)8.85%
Min EPS beat(4)3.16%
Max EPS beat(4)14.01%
EPS beat(8)7
Avg EPS beat(8)5.22%
EPS beat(12)9
Avg EPS beat(12)3.61%
EPS beat(16)11
Avg EPS beat(16)0.87%
Revenue beat(2)0
Avg Revenue beat(2)-7.1%
Min Revenue beat(2)-13.55%
Max Revenue beat(2)-0.65%
Revenue beat(4)1
Avg Revenue beat(4)-6.74%
Min Revenue beat(4)-59.88%
Max Revenue beat(4)47.11%
Revenue beat(8)4
Avg Revenue beat(8)247.34%
Revenue beat(12)6
Avg Revenue beat(12)238.35%
Revenue beat(16)8
Avg Revenue beat(16)201.02%
PT rev (1m)0.84%
PT rev (3m)12.84%
EPS NQ rev (1m)-0.83%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)0.29%
EPS NY rev (3m)4.82%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)-2.26%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.82
P/FCF N/A
P/OCF N/A
P/B 4.35
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-12.22
EYN/A
EPS(NY)-9.31
Fwd EYN/A
FCF(TTM)-8.5
FCFYN/A
OCF(TTM)-8.47
OCFYN/A
SpS0.54
BVpS13.49
TBVpS13.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.25%
ROE -76.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.5%
FCFM N/A
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.91%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.39
Altman-Z 8.55
F-Score4
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)466.3%
Cap/Depr(5y)417.11%
Cap/Sales(3y)28.4%
Cap/Sales(5y)26.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
EBIT growth 1Y-2.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.48%
EBIT Next 3Y-11.53%
EBIT Next 5YN/A
FCF growth 1Y-77.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.55%
OCF growth 3YN/A
OCF growth 5YN/A